Equipment coverage requires documented medical necessity

Durable nebulizer equipment and certain related HCPCS/CPT codes are covered only when the member meets the policy’s selection and medical necessity criteria; the plan of care must document the condition justifying medical necessity and the drug order must specify drug name, concentration or mg amount, and volume. Claims must include a narrative diagnosis and/or ICD code on each order and claim, and the patient's medical record must support medical necessity for all equipment, accessories, and drugs ordered.

• Equipment coverage contingent on meeting the listed indications and selection criteria in the policy.
• Plan of care and drug orders must include specific drug details (name, concentration/mg, and volume) and an accompanying narrative diagnosis/ICD code.
• Medical record must document support for medical necessity of equipment, accessories, and drugs.

Prior authorization required for nebulizer DME and listed nebulized drugs

Prior authorization is required per the policy for covered nebulizer equipment, accessories, and specified nebulized drug products when selection criteria are met; submit the applicable HCPCS/J-codes listed in the policy with the request.

• Include the HCPCS/J-codes indicated by the policy when requesting authorization.
• Requests for devices or drugs that meet selection criteria should be routed through prior authorization per plan rules.

Verify indication and device compatibility with product labeling

Verify the indication and that the prescribed device/delivery system matches product labeling (e.g., Cayston must be administered with the Altera Nebulizer System; Brovana/Perforomist are for COPD maintenance and have specific dosing constraints).

• Confirm Cayston (aztreonam) will be used with the Altera Nebulizer System per FDA labeling.
• Confirm Brovana (arformoterol) and Perforomist (formoterol) are prescribed only for indicated COPD maintenance use and following pharmacy criteria.
• For prostanoids (Tyvaso, Ventavis), verify device-specific delivery and dosing schedule and monitor for known adverse effects (e.g., bronchospasm).

Follow tobramycin dosing cycles and document supervised initiation and monitoring

When prescribing inhaled tobramycin, follow labeled dosing and monitoring: solution 300 mg inhaled every 12 hours (28 days on/28 days off) or Podhaler 4 × 28 mg (112 mg) every 12 hours (28 days on/28 days off); initial dose should be given under observation and baseline/ongoing renal and audiology monitoring documented when indicated.

• Tobramycin inhalation solution: 300 mg by inhalation over ~15 minutes q12h; administer via jet (breath-enhanced) nebulizer.
• Tobramycin inhalation powder (Podhaler): four 28 mg capsules (112 mg) inhaled q12h; use Podhaler device and store capsules in blister until use.
• Initial administration must occur in presence of trained health professional to monitor for bronchospasm; monitor BUN/creatinine and urinalysis and perform audiogram (500–8000 Hz) if concomitant nephrotoxic/ototoxic agents, preexisting dysfunction, or symptoms.

Prior authorization and justification required for out-of-cycle replacements

Requests for replacements of durable nebulizers or accessories beyond the policy’s listed 'usual maximum' replacement intervals may require prior authorization and must be justified with documentation supporting medical necessity.

• Provide physician confirmation of continued need, member compliance, and warranty status when requesting replacement.
• If the requested replacement frequency exceeds the policy’s usual maximum (e.g., face tent 1/month; small volume disposable nebulizer 2/month; durable bottle-type 1/3 years), include clinical justification.

No additional PA code list provided in policy text — use HCPCS/J-codes and selection criteria

The policy text in these chunks does not enumerate explicit prior authorization codes or a separate prior authorization process detail; use the HCPCS/J-codes and selection criteria listed in the policy when submitting requests and follow plan-specific PA procedures.

• No discrete PA form or code list is specified in these sections — include policy-based documentation and applicable HCPCS/J-codes with authorization requests.
• Follow the payer’s standard prior authorization submission pathways.

Document trial/consideration of MDI ± spacer before nebulizer when required

When criterion B (COPD/asthma drug delivery) applies, the physician must document that an MDI with or without a spacer was considered and found insufficient before a nebulizer is deemed necessary.

• Document attempted/considered MDI therapy (with or without spacer) and the clinical rationale why MDI was inadequate.
• Include this documentation in the plan of care and authorization request when applicable.

Prefer evidence-based inhaled antibiotics for CF with Pseudomonas

Evidence supports aerosolized tobramycin (TOBI/TNS) for maintenance therapy in CF patients chronically infected with Pseudomonas aeruginosa — consider tobramycin (or Cayston) per labeled indications and documented infection status.

• Ensure documentation of chronic Pseudomonas aeruginosa infection when requesting inhaled antibiotic therapy.
• Prefer agents and dosing regimens consistent with FDA labeling and clinical evidence (e.g., TOBI per FEV1/age labeling; Cayston using Altera system).

Prioritize supportive care for bronchiolitis; document rationale for bronchodilator/steroid use

For bronchiolitis and viral wheeze, supportive care (oxygenation, hydration, pulse oximetry) is first-line; bronchodilators and corticosteroids are not routinely effective and should not be used routinely without justification.

• Document supportive care measures and clinical rationale if bronchodilators or steroids are used despite limited evidence.
• Avoid routine authorization of nebulizer therapy for bronchiolitis unless specific documented indications exist.

Prefer IV magnesium for refractory pediatric asthma; justify nebulized magnesium if requested

Intravenous magnesium sulfate is supported for pediatric acute asthma refractory to initial therapy; nebulized magnesium has not demonstrated benefit — consider IV route before nebulized magnesium and document rationale if nebulized route is requested.

• If requesting nebulized magnesium, include evidence-based justification given meta-analysis showing benefit only for IV magnesium.
• Document prior treatments and reason for selecting nebulized vs IV route.

None specified

No additional provider actions are specified in this section.

Document alternatives tried, compliance, anticipated need, and warranty status

Physician must document that alternatives (e.g., MDI with or without spacer) were considered and found medically insufficient when required; for replacements include confirmation of compliance, anticipated continued need, and warranty expiration in documentation.

• Include documentation of alternative therapies tried and clinical rationale for nebulizer necessity.
• For replacements, include PCP/specialist confirmation of compliance, anticipated continued need, and warranty status.

Include complete plan of care and drug order details on requests

The plan of care and drug orders must specify the patient’s condition justifying medical necessity and must include the drug name, concentration or mg amount, and volume in each container; an ICD diagnosis code or narrative diagnosis must appear on each order and claim.

• Ensure the drug order includes exact drug name, concentration or mg amount, and volume.
• Include a narrative diagnosis and/or ICD code on each order and claim to support medical necessity.

Document supervised initial administration and renal/auditory monitoring for inhaled tobramycin

Document baseline and ongoing monitoring for patients on inhaled tobramycin: initial administration observed by a trained health professional to monitor for bronchospasm; monitor renal function (BUN/creatinine, urinalysis) and obtain audiograms when indicated (concomitant nephrotoxic/ototoxic agents, preexisting dysfunction, or symptoms).

• Initial dose should be given under supervision and technique education provided to patient/caregiver.
• Perform BUN/creatinine and urinalysis and audiogram (500–8000 Hz) when clinically indicated; document results and any adverse effects monitoring.

Monitoring and documentation requirements for inhaled tobramycin recipients

Specifically monitor and document renal function (BUN, creatinine, urinalysis) and audiology (audiogram 500–8000 Hz) for patients on inhaled tobramycin who are receiving concomitant nephrotoxic or ototoxic agents or have preexisting dysfunction; document patient/caregiver education on adverse effects and instructions to stop and notify clinician if symptoms occur.

• Document baseline labs and audiogram when indicated and repeat monitoring if symptoms or concomitant toxic therapies are present.
• Record patient/caregiver training on recognition of tinnitus, bronchospasm, urticaria, edema, and instructions to report adverse events.

Provide justification and documentation for replacement requests exceeding usual maximums

When requesting replacement frequencies that exceed the policy’s usual maximum intervals, include documentation supporting medical necessity (e.g., clinical reasons for increased replacement, proof of warranty expiration, and PCP/specialist confirmation of ongoing need).

• Reference the policy’s 'Usual Maximum Replacement' intervals and provide clinical justification for exceeding them.
• Attach evidence of member compliance and device failure/warranty expiration as applicable.

Record MDI ± spacer trials and rationale when required

Document that an MDI with or without a spacer was considered and found insufficient before requesting a nebulizer when the policy criteria require it; include this in the plan of care and prior authorization materials.

• Record specifics of MDI trial (drug, dose, spacer use, response) and the reason it was inadequate.
• Include clinician rationale and objective measures if available (e.g., peak flow, FEV1).

Therapeutic preference: follow evidence-based inhaled antibiotic indications and device requirements

Informational: evidence supports aerosolized tobramycin for maintenance therapy in CF patients chronically infected with Pseudomonas aeruginosa; ensure infection status is documented and dosing/device requirements (e.g., jet nebulizer or Podhaler; Cayston with Altera) are met.

• Confirm chronic Pseudomonas infection in documentation for inhaled antibiotic requests.
• Follow product-specific device and dosing instructions (Podhaler for tobramycin powder; Altera for Cayston).

Prefer IV route for magnesium in refractory pediatric asthma; justify nebulized use

Prefer IV magnesium sulfate for pediatric acute asthma refractory to initial therapy; nebulized magnesium has not shown significant benefit — if nebulized magnesium is requested, include justification referencing prior treatments and rationale.

• Document prior therapies and clinical reasoning for selecting nebulized rather than IV magnesium.
• Include relevant trial data or patient-specific contraindications to IV therapy if claiming neb route is necessary.

No actions specified in this section

No specific provider actions are listed in these chunks.

Experimental/investigational uses of nebulizers may be denied

Use of small volume, large volume, and ultrasonic nebulizers and accessories for indications not specifically listed in the policy is considered experimental/investigational and may result in denial; ensure requested use matches the policy’s listed indications.

• Confirm the requested indication is one of the policy’s listed medically necessary uses before submission.
• If the indication is not listed, expect potential denial as experimental/investigational.

Include narrative diagnosis/ICD code and supporting medical record with claims

Claims for equipment, accessories, and drugs must include a narrative diagnosis and/or ICD code describing the condition necessitating nebulizer therapy; the patient's medical record must support medical necessity for all items ordered.

• Include an ICD diagnosis and narrative statement of medical necessity on each order and claim.
• Attach relevant clinical documentation to support the request (e.g., cultures showing Pseudomonas for inhaled antibiotics).

Do not prescribe inhaled antibiotics without documented infection or prophylactic indication

Do not prescribe inhaled antibiotics (e.g., tobramycin, aztreonam) unless there is a proven or strongly suspected bacterial infection or a prophylactic indication; inhaled antibiotics used without such evidence increase resistance risk and are unlikely to be approved.

• Document microbiology results or clinical rationale demonstrating proven or strongly suspected infection when requesting inhaled antibiotics.
• Avoid prophylactic or empiric inhaled antibiotic use without documented indication; include justification if prophylactic use is claimed.

Tobramycin requests without documented infection are at high risk for denial

Prescribing tobramycin without a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to be approved and may be denied due to risk of resistance; ensure documentation of infection status and adherence to labeled dosing/cycles.

• Provide microbiology or clinical evidence of Pseudomonas infection when requesting tobramycin therapy.
• Include documentation of planned 28-day on/28-day off cycles and device type used.